(2000) Current and future clinical trials for alzheimer s disease: Evolving ethical concerns. Progress in Neuro-Psychopharmacology and Biological Psychiatry 24 , 1229-1249 /Issa AM, Keyserlingk EW. Current and future clinical tri- als for Alzheimer's disease: evolving ethical concerns. Prog ...
2017. Introduction to supplement: the current status of treatment of ALS. Amyotroph Lateral Scler Frontotemporal Degener 18(sup1):1-4. doi: 10.1080/21678421.2017.1361447Miller RG, Appel SH. Introduction to supplement: the current status of treatment for ALS. Amyotroph Lateral Scler ...
In May 2021,Aeterna Zentarisannounced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's dise...
1). This review examines the technical considerations for FUS-BBBO, emphasizing the current research to deliver therapeutics optimally. In the second part of this review, we discuss the current applications of FUS-BBBO in clinical trials involving neurodegenerative disorders, tumors, and other ...
Dr.Terry Heiman-Pattersonhas spearheaded 24 clinical trials, establishing key standards in ALS care. She has authored more than 50 groundbreaking papers on motor neuron diseases and published hundreds of papers, abstracts, and...
As a result, several potential practice-changing clinical trials have recently been completed on the diagnosis and treatment of glioma, and we have entered the epoch of molecular diagnostics, personalized immunotherapy and chemo- therapy in precision medicine. According to the CNS 5th edition, the ...
Here, we provide an overview of the promising therapeutic avenues for Batten disease, highlighting current FDA-approved clinical trials and prospective future treatments. Key points The FDA approval of the enzyme replacement therapy cerliponase alfa (Brineura) for the treatment of CLN2 Batten disease...
clinical trials for the treatment of primary and metastatic liver cancer (NCT01829971). Oncogenic or disease-progressing miRNAs can be preferentially inhibited by miRNA inhibitors. Several proprietary chemical modifications, such as 2’-O-methyl, 2’-fluoro, 2’-O-methoxyethyl, 2’,4’-methylene, ...
There are statistical methods for the analysis of clinical tri- als in the presence of informative noncompliance, includ- ing structural nested accelerated failure time models [12], the marginal structural proportional hazards approach [13], and the complier proportional hazards effect of treatment ...
Effi- cacy of Tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208:13–24. 11. Pavord ID, HoyteCLF, Lindsley AW, Ambrose CS, Spahn JD, Roseti SL, et al. Tezepelumab reduces exacerbations across ...